 |
| Foto: Sergio Barbosa / SBDCD-InCor |
A revista científica The Lancet Diabetes & Endocrinology publicou no último dia 27 de maio o artigo “Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel”, escrito pelo médico cardiologista Raul Dias Santos e outros. O texto do artigo está disponível em: http://dx.doi.org/10.1016/S2213-8587(16)30041-9
Atualmente, Santos é diretor da Unidade Clínica de Lípides do InCor HCFMUSP. Confira abaixo sua produção científica entre 2015 e 2016:
• Aneni EC, Oni ET, Martin SS, Blaha MJ, Agatston AS, Feldman T, Veledar E, Conçeição RD, Carvalho JA, Santos Filho RD, Nasir K. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. J Hypertens. 2015;33(6):1207-14.
Fator de Impacto: 4.720 (JCR)
• Feldman DI, Blaha MJ, Santos Filho RD, Jones SR, Blumenthal RS, Toth PP, Sperling LS, Martin SS. Recommendations for the management of patients with familial hypercholesterolemia. Curr Atheroscler Rep. 2015;17(1):473.
Fator de Impacto: 3.417 (JCR)
• Frota KM, Santos Filho RD, Ribeiro VQ, Arêas JA. Cowpea protein reduces LDL-cholesterol and apolipoprotein B concentrations, but does not improve biomarkers of inflammation or endothelial dysfunction in adults with moderate hypercholesterolemia. Nutr Hosp. 2015;31(4):1611-9.
Fator de Impacto: 1.040 (JCR)
• Harada PH, Canziani ME, Lima LM, Kamimura M, Rochitte CE, Lemos MM, Cuppari L, Kalil Filho R, Draibe SA, Santos Filho RD. Pericardial fat is associated with coronary artery calcification in non-dialysis dependent chronic kidney disease patients. PLoS One. 2015;9(12):e114358.
Fator de Impacto: 3.23 (JCR)
• Jannes CE, Santos Filho RD, Souza Silva PR, Turolla L, Gagliardi AC, Marsiglia JD, Chacra APC, Miname MH, Rocha VZ, Salgado Filho W, Krieger JE, Pereira AC. Familial hypercholesterolemia in Brazil: Cascade screening program, clinical and genetic aspects. Atherosclerosis. 2015;238(1):101-7.
Fator de Impacto: 3.994 (JCR)
• Katz M, Laurinavicius AG, Franco FG, Conceição RD, Carvalho JA, Pesaro AE, Wajngarten M, Santos Filho RD. Calculated and perceived cardiovascular risk in asymptomatic subjects submitted to a routine medical evaluation: the perception gap. Eur J Prev Cardiol. 2015;22(8):1076-82.
Fator de Impacto: 3.319 (JCR)
• Kootte RS, Smits L, van der Valk FM, Dasseux JL, Keyserling CH, Barbaras R, Paolini JF, Santos Filho RD, van Dijk TH, Dallinga-van Thie GM, Nederveen AJ, Mulder WJ, Hovingh GK, Kastelein JJ, Groen AK, Stroes ES. Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA. J Lipid Res. 2015;56(3):703-12.
Fator de Impacto: 4.421 (JCR)
• Miller PE, Martin SS, Toth PP, Santos Filho RD, Blaha MJ, Nasir K, Virani SS, Post WS, Blumenthal RS, Jones SR. Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17). J Clin Lipidol. 2015;9(5):676-83.
Fator de Impacto: 3.904 (JCR)
• Miname MH, Santos Filho RD. Fatty liver, inflamed blood and calcified coronary arteries: lessons and uncertainties from the multiethnic study of atherosclerosis-commentary on the study of Al Rifai et al. Atherosclerosis. 2015;239(2):634-6.
Fator de Impacto: 3.994 (JCR)
• Oni ET, Kalathiya R, Aneni EC, Martin SS, Blaha MJ, Feldman T, Agatston AS, Blumenthal RS, Conceiçao RD, Carvalho JA, Santos Filho RD, Nasir K. Relation of physical activity to prevalence of nonalcoholic fatty liver disease independent of cardiometabolic risk. Am J Cardiol. 2015;115(1):34-9.
Fator de Impacto: 3.276 (JCR)
• Pereira C, Miname MH, Makdisse MR, Watanabe C, Pesaro AE, Jannes CE, Kalil Filho R, Pereira AC, Santos Filho RD. Peripheral arterial disease in heterozygous familial hypercholesterolemia. Atherosclerosis. 2015;242(1):174-8.
Fator de Impacto: 3.994 (JCR)
• Rached F, Lhomme M, Camont L, Gomes F, Dauteille C, Robillard P, Santos Filho RD, Serrano Jr CV, Chapman MJ, Kontush A. Defective functionality of small, dense HDL3 subpopulations in ST segment elevation myocardial infaction: relevance of enrichment in lysophosphatidylcholine, phosphatidic acid and serum amyloid A. Biochim Biophys Acta. 2015;1851(9):1254-61.
Fator de Impacto: NT (JCR)
• Rosales C, Patel N, Gillard BK, Yelamanchili D, Yang Y, Courtney HS, Santos Filho RD, Gotto Jr AM, Powall HJ. Apolipoprotein AI deficiency inhibits serum opacity factor activity against plasma high density lipoprotein via a stabilization mechanism. Biochemistry. 2015;54(14):2295-302.
Fator de Impacto: 3.015 (JCR)
• Santos Filho RD, Frauches TS, Chacra AP. Cascade screening in familial hypercholesterolemia: advancing forward. J Atheroscler Thromb. 2015;22(9):869-80.
Fator de Impacto: 2.733 (JCR)
• Santos Filho RD, Raal FJ, Catapano AL, Witztum J, Steinhagen-Thiessen E, Tsimikas S. Mipomersen, an antisense oligonucleotide to apolipoprotein b-100, reduces lipoprotein(a) in various populations with hypercholesterolemia: results of 4 phase III trials. Arterioscler Thromb Vasc Biol. 2015;35(3):689-99.
Fator de Impacto: 6.000 (JCR)
• Santos Filho RD, Raal FJ, Donovan JM, Cromwell WC. Mipomersen preferentially reduces small low-density lipoprotein particle number in patients with hypercholesterolemia. J Clin Lipidol. 2015;9(2):201-9.
Fator de Impacto: 3.904 (JCR)
• Santos Filho RD, Watts GF. Familial hypercholesterolaemia: PCSK9 inhibitors are coming. Lancet. 2015;385(9965):307-10.
Fator de Impacto: 45.217 (JCR)
• Santos Filho RD, Duell PB, East C, Guyton JR, Moriarty PM, Chin W, Mittleman RS. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J. 2015;36(9):566-75.
Fator de Impacto: 15.203 (JCR)
• Scherr C, Gagliardi ACM, Miname MH, Santos Filho RD. Concentração de ácidos graxos e colesterol de peixes habitualmente consumidos no Brasil. Arq Bras Cardiol. 2015;104(2):152-8.
Fator de Impacto: 1.021 (JCR)
• Shaharyar S, Roberson LL, Jamal O, Younus A, Blaha MJ, Ali SS, Zide K, Agatston AA, Blumenthal RS, Conceição RD, Santos Filho RD, Nasir K. Obesity and metabolic phenotypes (metabolically healthy and unhealthy variants) are significantly associated with prevalence of elevated C-reactive protein and hepatic steatosis in a large healthy brazilian population. J Obes. 2015;2015:178526.
Fator de Impacto: NT (JCR)
• Stroes ES, Thompson PD, Corsini A, Raal FJ, Ray KK, Roden M, Stein E, Tokgözoğlu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos Filho RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, März W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society consensus panel statement on assessment, aetiology and management. Eur Heart J. 2015;36(17):1012-22.
Fator de Impacto: 15.203 (JCR)
• Sturrock A, Laule C, Wyper K, Milner RA, Decolongon J, Santos Filho RD, Coleman AJ, Carter K, Creighton S, Bechtel N, Bohlen S, Reilmann R, Johnson HJ, Hayden MR, Tabrizi SJ, Mackay AL, Leavitt BR. A longitudinal study of magnetic resonance spectroscopy Huntington's disease biomarkers. Mov Disord. 2015;30:393-401.
Fator de Impacto: 5.680 (JCR)
• Vallejo-Vaz AJ, Kondapally Seshasai SR, Cole D, Hovingh GK, Kastelein JJ, Mata P, Raal FJ, Santos Filho RD, Soran H, Watts GF, Abifadel M, Aguilar-Salinas CA, Akram A, Alnouri F, Alonso R, Al-Rasadi K, Banach M, Bogsrud MP, Bourbon M, Bruckert E, Car J, Corral P, Descamps OX, Dieplinger H, Durst R, Freiberger T, Gaspar IM, Genest J, Harada-Shiba M, Jiang L, Kayikcioglu M, Lam CS, Latkovskis G, Laufs U, Liberopoulos E, Nilsson L, Nordestgaard BG, O'Donoghue JM, Sahebkar A, Schunkert H, Shehab A, Stoll M, Su TC, Susekov A, Widén E, Catapano AL, Ray KK. Familial hypercholesterolaemia: a global call to arms. Atherosclerosis. 2015;243(1):257-9.
Fator de Impacto: 3.994 (JCR)
• Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, Bruckert E, Defesche J, Lin KK, Livingston M, Mata P, Parhofer KG, Raal FJ, Santos Filho RD, Sijbrands EJ, Simpson WG, Sullivan DR, Susekov AV, Tomlinson B, Wiegman A, Yamashita S, Kastelein JJ. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Eur J Prev Cardiol. 2015;22(7):849-54.
Fator de Impacto: 3.319 (JCR)
• Watts GF, Pang J, Santos Filho RD. Europe aspires to set the record straight on familial hypercholesterolaemia. Atherosclerosis. 2015;241(2):769-71.
Fator de Impacto: 3.994 (JCR)
• Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Borén J, Bruckert E, Catapano AL, Defesche JC, Descamps OS, Hegele RA, Hovingh GK, Humphries SE, Kovanen PT, Kuivenhoven JA, Masana L, Nordestgaard BG, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos Filho RD, Stalenhoef AF, Steinhagen-Tiessen E, Stroes ES, Taskinen MR, Tybjaerg-Hansen A, Wiklund O. Familial hypercholesterolaemia in children and adolescents: gainning decades of life by optimizing detection and treatment. Eur Heart J. 2015;36(36):2425-37.
Fator de Impacto: 15.203 (JCR)
• Al-Hashmi K, Al-Zakwani I, Al Mahmeed W, Arafah M, Al-Hinai AT, Shehab A, Al Tamimi O, Al Awadhi M, Al Herz S, Al Anazi F, Al Nemer K, Metwally O, Alkhadra A, Fakhry M, Elghetany H, Medani AR, Yusufali AH, Al Jassim O, Al Hallaq O, Baslaib FO, Amin H, Santos Filho RD, Al-Waili K, Al-Rasadi K. Non-high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian Gulf. J Clin Lipidol. 2016;10(2):368-77.
• Bittencourt MS, Staniak HL, Pereira AC, Santos IS, Duncan BB, Santos Filho RD, Blaha MJ, Jones SR, Toth PP, Bensenor IM, Lotufo PA. Implications of the New US Cholesterol Guidelines in the Brazilian Longitudinal Study of Adult Health (ELSA-Brasil). Clin Cardiol 2016. (in press).
• Laurinavicius AG, Bitencourt MS, Blaha MJ, Nary FC, Kashiwagi NM, Conceição RD, Meneghelo RS, Prado RR, Carvalho JA, Nasir K, Blumenthal RS, Santos Filho RD. Association between nonalcoholic hepatic steatosis and hyper reactive blood pressure response on the exercise treadmill test. QJM 2016. (in press).
• Santos Filho RD. PCSK9 inhibition in type 2 diabetes: so far so good, but not there yet. Lancet Diabetes Endocrinol 2016. (in press).
• Silva PR, Jannes CE, Marsiglia JD, Krieger JE, Santos Filho RD, Pereira AC. Predictors of cardiovascular events after one year of molecular screening for familial hypercholesterolemia. Atherosclerosis 2016. (in press).
• Thedrez A, Sjouke B, Passard M, Prampart-Fauvet S, Guédon A, Croyal M, Dallinga-Thie G, Peter J, Blom D, Ciccarese M, Cefalù AB, Pisciotta L, Santos Filho RD, Averna M, Raal F, Pintus P, Cossu M, Hovingh K, Lambert G. Proprotein convertase subtilisin kexin type 9 inhibition for autosomal recessive hypercholesterolemia. Arterioscler Thromb Vasc Biol 2016. (in press).Marcadores: artigo, dislipidemia, hipercolesterolemia familiar, InCor, Instituto do Coração, Lancet, publicação, Raul Dias Santos